Plus   Neg

Zoetis - Galloping To Glory


Shares of Zoetis Inc. (ZTS) touched an all-time high of $124.34 in intraday trading yesterday (Aug.7), and that represents a gain of nearly 47 percent year-to-date.

Zoetis is an animal health company - catering to the health of cattle, pigs, poultry, sheep, fish, dogs, cats and horses. The Company has roughly 300 product lines, which are sold in more than 100 countries.

Since 2016, there has been a year-over-year increase in revenue, thanks to a healthy demand for many of the Company's animal health products, the launch of new products, foray into additional markets, and acquisitions. Zoetis generates the largest revenue in the animal health medicines, vaccines, and diagnostics industry.

After acquiring Abaxis, a leader in the development, manufacture, and marketing of diagnostic instruments for veterinary point-of-care services for $2.0 billion in July 2018, Zoetis recently opened its wallet to make another acquisition. The Company acquired Platinum Performance, a privately held, nutrition-focused animal health company, in July of this year. Financial terms are being kept under wraps. The acquisition is expected to further strengthen and diversify Zoetis' portfolio in the equine and petcare markets.

The annual revenue was $5.83 billion in 2018 compared to $5.31 billion in 2017. Looking ahead to the full year 2019, the Company now expects revenue to range between $6.175 billion and $6.275 billion, slightly above its prior expectation of $6.100 billion and $6.225 billion.

We alerted our premium subscribers to Zoetis on June 30, 2014. (Report titled "Beyond Felines and Canines..."). At that time, the stock was trading at $32. Yesterday (Aug.8, 2019), the stock closed at $124.11, up 2.66%.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT